Agfa-Gevaert
Market Cap
€576.4m
Last Updated
2019/09/15 20:36 UTC
Data Sources
Company Financials +
Executive Summary
Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide.
Snowflake
Fundamentals
Moderate growth potential and overvalued.
Risks
- Agfa-Gevaert is covered by less than 3 analysts.
Similar Companies
Share Price & News
How has Agfa-Gevaert's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-5.6%
ENXTBR:AGFB
-1.8%
BE Healthcare Services
2.5%
BE Market
1 Year Return
-12.7%
ENXTBR:AGFB
-17.3%
BE Healthcare Services
3.3%
BE Market
AGFB outperformed the Healthcare Services industry which returned -17.3% over the past year.
AGFB underperformed the Market in Belgium which returned 3.3% over the past year.
Share holder returns
| AGFB | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.6% | -1.8% | 2.5% |
| 30 Day | 4.7% | 1.8% | 3.4% |
| 90 Day | -2.7% | -14.0% | 8.3% |
| 1 Year | -12.7%-12.7% | -16.3%-17.3% | 5.6%3.3% |
| 3 Year | 30.4%30.4% | 15.4%10.7% | -1.8%-8.8% |
| 5 Year | 64.9%64.9% | 98.7%84.8% | 23.1%7.8% |
Price Volatility Vs. Market
How volatile is Agfa-Gevaert's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
The Agfa-Gevaert (EBR:AGFB) Share Price Has Gained 63% And Shareholders Are Hoping For More1 month ago | Simply Wall St
Is Agfa-Gevaert (EBR:AGFB) Using Too Much Debt?3 months ago | Simply Wall St
Did You Miss Agfa-Gevaert's (EBR:AGFB) 60% Share Price Gain?Valuation
Is Agfa-Gevaert undervalued based on future cash flows and its price relative to the stock market?
2.08x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Agfa-Gevaert to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Agfa-Gevaert to establish if it is available at substantial discount.
Price Based on Earnings
Agfa-Gevaert is loss making, we can't compare its value to the Europe Healthcare Services industry average.
Agfa-Gevaert is loss making, we can't compare the value of its earnings to the Belgium market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Agfa-Gevaert, we can't assess if its growth is good value.
Price Based on Value of Assets
Agfa-Gevaert is good value based on assets compared to the Europe Healthcare Services industry average.
Next Steps
Future Growth
How is Agfa-Gevaert expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
-0.5%
Forecasted annual revenue growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Agfa-Gevaert's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Agfa-Gevaert's earnings are expected to grow significantly at over 20% yearly.
Agfa-Gevaert's revenues are expected to decrease over the next 1-3 years, this is below the Belgium market average.
Agfa-Gevaert's earnings growth is expected to exceed the Belgium market average.
Agfa-Gevaert's earnings growth is expected to exceed the low risk savings rate of 0.8%.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Agfa-Gevaert will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Next Steps
Past Performance
How has Agfa-Gevaert performed over the past 5 years?
-34.8%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Agfa-Gevaert does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Agfa-Gevaert's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Agfa-Gevaert's 1-year growth to the Europe Healthcare Services industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Agfa-Gevaert has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Agfa-Gevaert has efficiently used its assets last year compared to the Europe Healthcare Services industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Agfa-Gevaert improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Agfa-Gevaert's financial position?
Financial Position Analysis
Agfa-Gevaert is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Agfa-Gevaert's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Agfa-Gevaert's level of debt (124.5%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has increased over the past 5 years (81.2% vs 124.5% today).
Operating cash flow is negative therefore debt is not well covered.
Agfa-Gevaert is making a loss, therefore interest payments are not well covered by earnings.
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 3.3x debt.
Next Steps
Dividend
What is Agfa-Gevaert's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Agfa-Gevaert's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Agfa-Gevaert's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Agfa-Gevaert has not reported any payouts.
Unable to verify if Agfa-Gevaert's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Agfa-Gevaert has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Agfa-Gevaert's salary, the management and board of directors tenure and is there insider trading?
11.0yrs
Average management tenure
CEO
Christian Reinaudo (65yo)
9.3yrs
Tenure
€4,815,879
Compensation
Mr. Christian Reinaudo has been Chairman at Biocartis Group NV since May 2018. He has been the Chief Executive Officer and Executive Director at Agfa-Gevaert Limited since May 1, 2010 and 2010 respectively ...
CEO Compensation Analysis
Christian's remuneration is higher than average for companies of similar size in Belgium.
Christian's compensation has increased whilst company is loss making.
Management Age and Tenure
11.0yrs
Average Tenure
55yo
Average Age
The average tenure for the Agfa-Gevaert management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
1.3yrs
Average Tenure
60yo
Average Age
The average tenure for the Agfa-Gevaert board of directors is less than 3 years, this suggests a new board.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Christian Reinaudo (65yo)
CEO, President & Executive Director
- Tenure: 9.3yrs
- Compensation: €4.82m
Stefaan Vanhooren (55yo)
President of Agfa Graphics
- Tenure: 15.7yrs
- Boyer
Executive Vice President
- Tenure: 0yrs
Luc Delagaye (59yo)
President of Agfa Materials
- Tenure: 11.3yrs
Luc Thijs (54yo)
President of Agfa Healthcare
- Tenure: 0yrs
Dirk De Man
Chief Financial Officer
- Tenure: 1.3yrs
Wilfried Van Lishout (55yo)
Compliance Officer & Company Secretary
- Tenure: 0yrs
Viviane Dictus
Director of Corporate Communications
- Tenure: 11yrs
Board Members
Jo Cornu (75yo)
Independent Director
- Tenure: 17.7yrs
- Compensation: €70.00k
Christian Reinaudo (65yo)
CEO, President & Executive Director
- Tenure: 9.3yrs
- Compensation: €4.82m
Hilde Laga (63yo)
Independent Director
- Tenure: 4.3yrs
- Compensation: €70.00k
Helen Routh (57yo)
Independent Director
- Tenure: 0.3yrs
Klaus Röhrig (42yo)
Chairman of the Board
- Tenure: 0.3yrs
- Compensation: €25.00k
Mark Pensaert (55yo)
Independent Director
- Tenure: 1.3yrs
- Compensation: €75.00k
Frank Aranzana
Director
- Tenure: 0.3yrs
Company Information
Agfa-Gevaert NV's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Agfa-Gevaert NV
- Ticker: AGFB
- Exchange: ENXTBR
- Founded: 1867
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: €576.393m
- Shares outstanding: 167.75m
- Website: https://www.agfa.com
Number of Employees
Location
- Agfa-Gevaert NV
- Septestraat 27
- Mortsel
- Antwerp
- 2640
- Belgium
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AGFB | ENXTBR (Euronext Brussels) | Yes | Ordinary Shares | BE | EUR | Jun 1999 |
| AGE | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jun 1999 |
| 0MFU | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jun 1999 |
| AGFBB | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jun 1999 |
| AGFB | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | Jun 1999 |
| AFGV.Y | OTCPK (Pink Sheets LLC) | ADR | US | USD | Oct 2008 |
Biography
Agfa-Gevaert NV develops, produces, and distributes various analog and digital imaging systems, and IT solutions worldwide. The company operates through three segments: Agfa Graphics, Agfa HealthCare, and ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/15 20:36 |
| End of Day Share Price | 2019/09/13 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.